Home  About us  Contact
 

Adrenergic Receptor Agonists (adrenergic + receptor_agonist)

Distribution by Scientific Domains
Chemistry60%
Medical Sciences40%

Selected Abstracts

Application of the Lewis Acid,Lewis Base Bifunctional Asymmetric Catalysts to Pharmaceutical Syntheses: Stereoselective Chiral Building Block Syntheses of Human Immunodeficiency Virus (HIV) Protease Inhibitor and ,3 -Adrenergic Receptor Agonist.

CHEMINFORM, Issue 44 2003
Hiroyuki Nogami
Abstract For Abstract see ChemInform Abstract in Full Text. [source]

Adipocyte prolactin: regulation of release and putative functions

DIABETES OBESITY & METABOLISM, Issue 4 2007
T. Brandebourg
Pituitary-derived prolactin (PRL) is a well-known regulator of the lactating mammary gland. However, the recent discovery that human adipose tissue produces PRL as well as expresses the PRL receptor (PRLR) highlights a previously unappreciated action of PRL as a cytokine involved in adipose tissue function. Biologically active PRL is secreted by all adipose tissue depots examined: breast, visceral and subcutaneous. The expression of adipose PRL is regulated by a non-pituitary, alternative superdistal promoter. PRL expression and release increases during early pre-adipocyte differentiation and is stimulated by cyclic AMP activators, including , adrenergic receptor agonists. PRL release from subcutaneous adipose explants is attenuated during obesity, suggesting that adipose PRL production is altered by the metabolic state. Several lines of evidence indicate that PRL suppresses lipid storage as well as the release of adipokines such as adiponectin, interleukin-6 and possibly leptin. PRL has also been implicated in the regulation of adipogenesis. A newly developed PRL-secreting human adipocyte cell line, LS14, should allow comprehensive examination of the regulation and function of adipocyte-derived PRL. Collectively, these studies raise the prospect that PRL affects energy homeostasis through its action as an adipokine and is involved in the manifestation of insulin resistance. [source]

Convergent synthesis of two 14C-labeled ,3 -adrenergic receptor agonists

JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, Issue 8 2006
Boris A. Czeskis
Abstract The synthesis of ,3 -adrenergic receptor agonists A and B with radiolabeled amide fragment, required for drug disposition studies, was accomplished based on initial formation of 2-(4-(2-amino-2-methylpropyl)phenoxy)-5-[14C]-cyanopyridine by the reaction of 2-bromo-5-iodopyridine with para -substituted phenol, and following cyanation of aromatic iodide with potassium cyanide-[14C]. After the coupling of the resulted amine with glycidyl derivatives of 4-hydroxyindole and 4-hydroxycarbazole, the corresponding nitriles were hydrolyzed with basic hydrogen peroxide to obtain target amides A and B. Copyright © 2006 John Wiley & Sons, Ltd. [source]

Chronic inhaled corticosteroids do not affect the course of acute severe asthma exacerbations in children,

PEDIATRIC PULMONOLOGY, Issue 12 2006
Christopher L. Carroll MD
Abstract Chronic therapy with inhaled corticosteroids (ICS) suppresses airway inflammation and increases airway responsiveness to ,2 -adrenergic receptor agonists. We hypothesized that the chronic use of ICS would be associated with shorter duration of hospitalization in severely ill children with status asthmaticus. An 8-year retrospective chart review was conducted of all children admitted to the ICU with status asthmaticus. During the study period, 241 children were admitted, and 44% reported the use of chronic ICS. ICS use was associated with increased baseline asthma severity, previous hospitalization for asthma, and public insurance status. However, ICS use had no effect on hospital or ICU length of stay, type, and duration of treatments received, or the rate of recovery determined by a standard severity of illness scoring system. In the subsets of patients including children with persistent asthma and those who received intravenous terbutaline, there was also no improvement in outcomes with the use of chronic ICS showing that the chronic use of ICS did not improve response to ,2 -adrenergic receptor agonists in severely ill children with status asthmaticus. Although useful as a preventive therapy, the chronic use of ICS does not appear to affect the course of severe acute asthma exacerbations in pediatric patients once hospitalized. Pediatr Pulmonol. 2006; 41: 1213,1217. © 2006 Wiley-Liss, Inc. [source]